Harmine and Other β-Carboline Compounds Inhibit Tau Phosphorylation
Author Information
Author(s): Danielle Frost, Bessie Meechoovet, Tong Wang, Stephen Gately, Marco Giorgetti, Irina Shcherbakova, Travis Dunckley
Primary Institution: Translational Genomics Research Institute
Hypothesis
Can β-carboline compounds inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites?
Conclusion
The study found that β-carboline compounds, particularly harmine, significantly reduce tau phosphorylation, suggesting their potential as therapeutic agents for Alzheimer's disease.
Supporting Evidence
- Harmine was shown to inhibit DYRK1A activity with an IC50 of approximately 0.7 µM.
- The study demonstrated that harmine significantly reduced levels of phosphorylated tau at multiple sites.
- Additional β-carboline derivatives were tested and showed varying effects on tau phosphorylation.
Takeaway
Researchers found that a natural compound called harmine can help reduce a harmful protein linked to Alzheimer's disease in brain cells.
Methodology
The study used cell culture assays and in vitro phosphorylation assays to test the effects of β-carboline compounds on tau phosphorylation.
Potential Biases
Potential conflicts of interest due to funding from MediProPharma, Inc.
Limitations
The study did not explore the long-term effects of these compounds on tau pathology in vivo.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website